---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055062"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T12:31:48.794187+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics Q1 2024 net loss $37.9M ($0.35/sh); cash $343.6M funds into late 2026

## Summary
- Net loss of $37.9M, or $0.35 per share, vs $28.0M ($0.32) in Q1 2023.
- Cash, equivalents and marketable securities of $343.6M as of March 31, 2024.
- R&D expense rose to $38.1M from $28.0M due to clinical program advancement.
- Dose expansion initiated for TNG908 (PRMT5 inhibitor) in MTAP-deleted tumors.
- PRMT5 clinical data update expected in 2H 2024; TNG462 expansion expected Q2 2024.

## SEC filing metadata
- accession: 0000950170-24-055062
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000095017024055062/0000950170-24-055062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000095017024055062/tngx-20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055062
- JSON: https://secwatch.observer/filing/0000950170-24-055062.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055062.txt

## Key facts
- Earnings Releases
  Tango Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $6.5 million, net income $37.9 million, EPS $0.35 per share.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $6.5 million
  - Net income: $37.9 million
  - EPS: $0.35 per share
  - Result: reported results
  source text: held $343.6 million in cash, cash equivalents and marketable securities, which the Company expects to be sufficient to fund operations into late 2026. Collaboration revenue was $6.5 million for the three months ended March 31, 2024, compared to $5.8 million for the same period in 2023. Research costs incurred under the collaboration were similar during each of the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000095017024055062/0000950170-24-055062-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.